In response to dwindling revenues from patent expirations, drug companies are aggressively raising prices on their branded offerings. According to the IMS Institute for Healthcare Informatics, $20B of the pharmaceutical industry's 2013 sales growth was due to price increases. This perfectly offset the $19.3B in revenue declines.
Since 2007, the CPI has risen 12% while some drug prices have inflated as much as 400%.
Therapies that cost $300K or more are becoming more common in light of the incentives afforded by the Orphan Drug Act.
Generics comprise 86% of all prescriptions filled but American spent $263B for medicines in 2012, up 11% from 2007's $236B.
Unsurprisingly, industry representatives insist that the proper focus should be on outcomes instead of prices. They also cite the ever-rising cost of R&D.